Urogen Pharma LTD. – Ordinary Shares (NASDAQ:URGN) Shares Shorted Strengthened By 21.63%

May 3, 2018 - By Sarah Harris

It was registered an increase on Urogen Pharma LTD. – Ordinary Shares (NASDAQ:URGN)’s shorted shares with 21.63%. FINRA published in May URGN’s total 206,900 shorted shares. The up change of 21.63% from 170,100 shares was reported. 2 days will cost URGN with 100,300 average volume to recover its former position. 2.43% is Urogen Pharma LTD. – Ordinary Shares float short.

Ticker’s shares touched $56.77 during the last trading session after 0.87% change.Currently UroGen Pharma Ltd. is after 0.00% change in last May 3, 2017. URGN has also 63,647 shares volume. The stock underperformed the S&P 500 by 11.55%.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies.The firm is worth $878.46 million. The Company’s lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water formulation as an adjuvant, or supplemental post-surgery, therapy.Last it reported negative earnings. The firm is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.

UroGen Pharma Ltd. (NASDAQ:URGN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.